5 recruiting, 3 active not recruiting, 1 suspended. 6 Phase 2, 3 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Recruiting 3 |
| Not applicable | 3 | Recruiting 2, Suspended 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Langerhans Cell Histiocytosis (LCH): new trials by email Literature Review of Langerhans Cell Histiocytosis (LCH) trials Research Report on Langerhans Cell Histiocytosis (LCH)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions Luvometinib - Langerhans Cell Histiocytosis (LCH) | Not applicable | Recruiting | West China Second University Hospital | 62 | 2026-06-19 | 2026-01-27 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis Prednisone, Vincristine, Mercaptopurine - Langerhans Cell Histiocytosis (LCH) | Not applicable | Recruiting | West China Second University Hospital | 120 | 2026-02-13 | 2026-02-24 |
| Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH Selinexor, Thalidomide (100mg), Dexamethasone - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2025-08-01 | 2025-10-02 |
| Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children Dabrafenib or Trametinib and Clofarabine - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Recruiting | West China Second University Hospital | 20 | 2025-06-01 | 2025-06-15 |
| Mirdametinib in Histiocytic Disorders Mirdametinib - Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG) | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 40 | 2024-02-05 | 2026-09-21 |
| Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease Genetic testing - Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH) | Not applicable | Suspended | Case Comprehensive Cancer Center | 135 | 2021-06-18 | 2026-10-06 |
| Lenalidomide for Adult Histiocyte Disorders Lenalidomide - Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 12 | 2015-08-01 | 2026-07-23 |
| CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation CD34 Stem Cell Selection Therapy - Bone Marrow Failure Syndrome, Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | Diane George | 37 | 2013-03-01 | 2025-08-14 |
Histiocytosis, Langerhans-Cell (9) · Erdheim-Chester Disease (2) · Acquired Immunodeficiency Syndrome (1) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1) · Bone Marrow Failure Disorders (1) · Carcinoma, Non-Small-Cell Lung (1) · Castleman Disease (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Hemoglobinopathies (1) · Histiocytic Sarcoma (1)
Hemic and Lymphatic Diseases (9) · Lung Diseases (9) · Lung Diseases, Interstitial (9) · Lymphatic Diseases (9) · Respiratory Tract Diseases (9) · Histiocytosis (8) · Histiocytosis, Non-Langerhans-Cell (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Digestive System Diseases (2) · Genital Diseases (2) · Hematologic Diseases (2) · Lymphoproliferative Disorders (2) · Urogenital Diseases (2) · Adenocarcinoma (1)
dabrafenib (2) · trametinib (2) · Clofarabine (1) · Dexamethasone (1) · Genetic Testing (1) · Lenalidomide (1) · Mercaptopurine (1) · Prednisone (1) · Thalidomide (1) · Vincristine (1) · mirdametinib (1) · selinexor (1)
West China Second University Hospital (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cancer Research UK (1) · Case Comprehensive Cancer Center (1) · Children's Hospital Medical Center, Cincinnati (1) · Dana-Farber Cancer Institute (1) · Diane George (1)
China (4) · United States (4) · United Kingdom (1)
Allison Bartlett, MD (1) · Ashish Kumar, MD, PhD (1) · Diane George, MD (1) · Eric Jacobsen, MD (1) · Ju Gao, MD (1) · Matthew Krebs (1) · Sudipto Mukherjee, MD, PhD (1)
PMID 31513482, PMID 32106306, PMID 36884302, PMID 37731389, PMID 15049016, PMID 29263218, PMID 33958797, PMID 37216396, PMID 38501389, PMID 38501390, PMID 40167581, PMID 40751881, PMID 41035796, PMID 18623218, PMID 19731321, PMID 23109216, PMID 23255383, PMID 23589673, PMID 26194764, PMID 29594922, PMID 30693828, PMID 36759117, PMID 38231288, PMID 39486044, PMID 41135521